JPRN-UMIN000033854已完成未知
A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intake - A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intake
HUMA R&D CORP0 个研究点目标入组 62 人开始时间: 2018年9月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 69years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)A person who is currently receiving any drug treatment or ambulatory treatment. 2)A person who is currently exercising or taking diet under the supervision of a physician. 3)Patients with a history of, present disease, or complication of liver disease or serious renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease. 4)Patients with chronic diseases (arrhythmias, hepatic disorders, renal disorders, cerebrovascular disorders, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or other chronic diseases) who are being treated or have a history 5)Patients who have undergone gastrointestinal surgery (appendicitis is acceptable) 6)Patients with eye diseases other than refractive error (hyperopia, myopia, astigmatism) 7)Persons with a history of drug or food allergy 8)People who wish to do so during pregnancy, lactation, or the duration of the study 9)Persons who have received blood donations or immunizations within the last 3 months or who plan to receive them during the study period. 10)Persons who routinely consume health foods, supplements, and pharmaceuticals that may affect ocular function. 11)Persons with psychiatric disorders (depression, etc.) or sleep disorders who are attending hospital or who have a history of psychiatric illness in the past 12)Alcoholics, addicts, or abusers with or without a history of treatment 13)Persons who work on a shift basis, such as those who work at night 14)Persons with extremely irregular lifestyle habits such as diet and sleep 15)Current smokers 16)Currently participating in other clinical trials or participating in other clinical trials within the last 3 months of the date of informed consent 17)Persons with difficulties in observing records on various questionnaires 18)Other persons who are judged by the investigator to be inappropriate for the study.
研究者
相似试验
进行中（未招募）
1 期
A 2-part trial to learn more about how BAY1817080 works, how safe it is, and what the right dose is for participants with diabetic neuropathic paieuropathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852EUCTR2020-002066-14-HUBayer AG440
进行中（未招募）
1 期
A 2-part trial to learn more about how BAY1817080 works, how safe it is, and what the right dose is for participants with diabetic neuropathic paieuropathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852EUCTR2020-002066-14-DKBayer AG440
进行中（未招募）
1 期
A study to test whether study drug BAY1128688 brings pain relief to women with endometriosis and if so to get a first idea which dose(s) work best.MedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2017-000244-18-ATBayer AG120
进行中（未招募）
1 期
A Phase 2a, randomized, placebo-controlled, double-blind study to investigate REM0046127 in mild to moderate Alzheimer's diseaseMedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 100000004852Alzheimer's DiseaseEUCTR2022-000080-43-ESreMYND60
进行中（未招募）
1 期
A study to learn how well the study treatment zabedosertib (BAY1834845) works and how safe it is compared to placebo in adult participants with moderate-to-severe atopic dermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2022-000520-38-FRBayer AG72